TXA and Corona Virus 2019 (COVID19) in Outpatients

Stopped early · Phase 2 · Has a placebo group

Conditions studied: COVID-19

In brief

A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

Key facts

Study ID

NCT04338074

Run by

University of Alabama at Birmingham

People needed

5

Starts

2020-06-01

Expected to finish

2021-04-21

Last updated by the study team

2021-05-13

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Positive COVID-19 test
• Outpatient
• Age >/= 19 y.o.

You may not qualify if…

• Allergic reaction to tranexamic acid
• History of hypercoagulation disorders (deep venous thrombosis, pulmonary thromboembolism)
• Ongoing anticoagulation
• History of GI bleeding
• History of Seizures
• Cardiac or other vascular stents
• History of severe renal disease
• History of intracranial hemorrhage

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.